Follicum announced today that it has received an Intention to grant from the European Patent Office (EPO) regarding its patent application No. 16169698.4 which protects the product candidate FOL-005.
In this patent family, Follicum has already a granted product patent in Europe that specifically covers FOL-005. Follicum has subsequently submitted a follow-up, a so called “Divisional” application, which extends and broadens the protection around FOL-005. Follicum has now received a preliminary approval for this divisional application. The patent covers the drug candidate FOL-005 and related substances. Some administrative steps remain before the patent is formally granted by the EPO. The granted patent confers protection in Europe until the year 2032.
CEO Jan Alenfall comments
-Europe is one of the absolute largest markets for Follicum, why this intention to grant communication is of major importance to us. We are continuously working to strategically expand our patent portfolio in our key markets.
FOL-005 is a modified short version of the endogenous protein, osteopontin. In two completed clinical studies, FOL-005 proved to be an effective and safe treatment. Already after three months of treatment, a clear effect on hair growth could be detected. The patients have been injected three times a week in these studies. As the next step in the development, the company will plan to start a clinical effect study with a topical formulation of FOL-005 where dose, dosage frequency and treatment length will be optimized. In parallel, the company will focus on finding a suitable development partner for FOL-005.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 21 November 2018.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.